SCHEMBL4223069

SCHEMBL4223069

CC(=O)Nc1cccc(Nc2cc(-c3ccccc3)ccc2C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 1/20 0.61
ABCG2 Q9UNQ0 2/20 0.56
ABCB1 P08183 1/20 0.56
ABCC1 P33527 1/20 0.56
HDAC1 Q13547 4/20 0.52
KDM4E B2RXH2 2/20 0.52
APOBEC3A P31941 1/20 0.52
GFER P55789 1/20 0.52
APOBEC3G Q9HC16 1/20 0.52
GRIK1 P39086 1/20 0.52
HDAC3 O15379 1/20 0.51
HDAC2 Q92769 1/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
ACLY P53396 2/20 0.51
NQO2 P16083 2/20 0.50
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
NPC1 O15118 1/20 0.50
TSHR P16473 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31312483 0.88 MPO (0.76) MPOABCG2ABCB1ABCC1KDM4E
SCHEMBL4223666 0.87 SIRT2 (0.61) GFERGRIK1ACLYAKR1C3AKR1C2
SCHEMBL4223041 0.85 MPO (0.60) MPOGRIK1MEN1KMT2ANQO2
SCHEMBL4214423 0.85 ABCG2 (0.52) MPOABCG2ABCB1ABCC1HDAC1
SCHEMBL4223119 0.84 AKR1C3 (0.60) GFERGRIK1ACLYAKR1C3AKR1C2
SCHEMBL4222620 0.84 AKR1C3 (0.66) MEN1KMT2AACLYAKR1C3AKR1C2
SCHEMBL7674275 0.83 HDAC1 (0.69) HDAC1KDM4EAPOBEC3AGFERAPOBEC3G
SCHEMBL4212934 0.82 SIRT2 (0.52) GRIK1ACLYAKR1C3AKR1C2TSHR
SCHEMBL4222990 0.81 ACLY (0.59) GFERGRIK1ACLYAKR1C3AKR1C2
SCHEMBL4225722 0.81 AKR1C3 (0.64) KDM4EGFERGRIK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 MPO 192/4885ABCG2 2248/4885ABCB1 2878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.